The Center for Metabolomics develops biomarkers of toxicity and disease. The core metabolomic facility is equipped with a Bruker 600 MHz nuclear magnetic resonance (NMR) that has a cryoprobe to analyze endogenous metabolites in biological samples. Capabilities of performing mass spectrometry (MS)-based metabolomic analysis have been expanded with the addition of a Waters UPLC-Qtof mass spectrometer system and Agilent GC mass spectrometer system.  The group has initially focused on the development of biomarkers of acute toxicity that can be applied to a variety of  research questions. Currently the group is evaluating the effects of renal, liver, and cardiotoxins using serum, urine, and various tissues. This technology is readily applicable to cross-species comparisons and for preclinical and clinical studies. NCTR is using Scaled-to-Maximum, Aligned, and Reduced Trajectories (SMART) analysis to map trajectories of change in physiological space to expand its ability to conduct cross-species analysis.

Contact Information

For more information, please contact Dr. Richard Beger at 870-543-7080 or richard.beger@fda.hhs.gov